+86-576-88205808
Eculizumab is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor.In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death.Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.
Related Products:
Alirocumab; Denosumab; Evolocumab; Omalizumab; Ustekinumab; Vedolizumab; Trastuzumab; Omalizumab; Nivolumab; Denosumab; Cetuximab; Bevacizumab; Aflibercept
Copyright Copyright (C) 2018-2024 Taizhou Crene Biotechnology Co.,Ltd.
Address:Economic Developed Zone of Taizhou Zhejiang China